



TECHNOLOGY TRANSFER COMMUNITY NEWSLETTER

October 2017



ETT System — Introduction

Exciting Changes Coming to the NIH Technology Transfer Community

David Vizmer, Sapient

Based on feedback from the NIH technology transfer community, NIH Advisory Committees, and Congress, the NIH has identified the need for a centralized IT platform to support technology transfer, replacing the patchwork of systems currently in use and maintained by technology transfer offices within the institutes and centers (IC). To implement this new platform, the NIH Capital Improvement Fund has committed the necessary funding, through the Office of Technology Transfer, to develop the Enterprise Technology Transfer (ETT) System.

The ETT System will be developed in partnership with the Office of Technology Transfer and the technology transfer offices within the ICs. A Project Governance Group, made up of high-level stakeholders from the technology transfer community, is meeting on a monthly basis to provide oversight and guidance for the system throughout its development and ongoing improvement.

Recognizing the complex interrelationship between the various technology transfer offices, researchers and external stakeholders, and the complexity of the resulting system requirements, the Office of Technology Transfer elected to perform a full scale analysis of the stakeholder needs, business processes and workflows, prior to selecting a core application as the foundation of the ETT system. Bringing together subject matter experts with in-depth knowledge of the activities performed by the technology transfer teams within the ICs, the ETT project team is establishing a high-level working group and dedicated focus groups to analyze the various business processes, develop and prioritize a set of functional requirements and review the commercial and government "off-the-shelf" systems available. Once a core system has been selected, the development team will work under the oversight of the ETT Project Governance Group to install, configure and customize the selected system to implement the initial set of features.

continued



In This Issue

| | |
|--|---|
| Enterprise Technology Transfer (ETT) System..... | 1 |
| NCI TT Seminar Series | 2 |
| Licensing Forum Discussion Group | 3 |
| DDIR Innovation Awards | 3 |
| NIH Helpdesk Tickets for OTT Requests..... | 4 |
| TechTracS | |
| Reminder about New End Users | 4 |
| Detecting Notices of Recordation Discrepancies | 5 |
| FY-2016 Top 20 Commercially Successful Inventions..... | 6 |
| New TT Community Staff Members..... | 7 |

ETT System — Introduction

continued from page 1

After the initial implementation and customization of the ETT system, the PGG will prioritize and group additional features not included in the initial release to allow the Office of Technology Transfer to facilitate the implementation of these features on an ongoing basis throughout the life of the system. This ongoing improvement is the key to maintaining a system that not only provides the functionality currently needed by the technology transfer community, but also grows with the community, addressing new requirements as user needs evolve.

In order to provide the community visibility into the progress of the ETT System, OTT has created a SharePoint site with information about the project, a timeline of what to expect when and a place to find relevant documentation and project plans as they are developed. Check in regularly at <https://spweb.od.nih.gov/OTT/DTDT/ETT/> to keep track of progress and stay up to date on plans!

If you have any questions about the project, or would like to volunteer your time to participate in one of the focus groups, please ask your supervisor to reach out to the ETT Project Governance Group for more information.

NCI Technology Transfer Seminar Series Offers NIH OTT Platform to Share Best Practices, Ensure that an NIH License Accomplishes Its Intended Goal

Michele Newton, NCI

Bruce Goldstein, OTT Monitoring and Enforcement, and Karen Rogers, OTT Royalties Administration, participated in the NCI Technology Transfer Seminar Series on September 14, delivering a presentation entitled “Show Me the Money.” In addition to those who attended the presentation in-person at NCI’s office in Rockville, more than 50 NIH TT Staff joined the presentation via WebEx.

About the Presentation: A signed license is a notable achievement, but the work of ensuring the technology reaches the public does not end there. Making sure the licensee does as promised usually involves paying close attention to what they report, maintaining a good working relationship with the licensee, sleuthing to find and verify information, and carefully applying the right variety of the tools and tactics of enforcement. All of these can be enabled, enhanced, circumscribed, or frustrated by the language in the agreement. By attending the presentations, attendees learned how the OTT Royalty Administration Unit and the Monitoring and Enforcement Unit carries out these tasks, and tips on how to ensure the license accomplishes its intended goal.

The NCI TT Seminar Series is organized by NCI TTC and takes place the second Thursday of the month at 2:00 PM. These seminars, featuring a range of TT related topics and presenters, are open to and attended by the NIH TT community and relevant NIH stakeholders.

Ask Steve? – Licensing Forum Discussion Group Moves to Tuesdays!

Steve Ferguson, NIH-OTT

St. Regis Mohawk Nation? Brexit Effects? Royalty Buyouts? These topics and more have all been covered in recent questions and discussions at the Tuesday (formerly Friday) Licensing Forum. Led by OTT's Steve Ferguson, the program has moved to Tuesdays at 2pm in order to better accommodate schedules of the now 100+ participants from the NIH tech transfer community. No licensing question or topic is considered too basic or too advanced – the idea is to share the collective wisdom and experiences of the community to advance PHS licensing programs.

To join the WebEx calendar invite and receive the agenda & questions for the week – just send an email note to Steve Ferguson at sf8h@nih.gov. Have your own licensing question or discussion topic for an upcoming session? Just ask Steve!



DDIR Innovation Awards

Karen Rogers, NIH-OTT

2017 marked the inaugural year for the DDIR Innovation Awards program. The program provides seed money to stimulate innovative, high-impact research, and to foster collaborations. The program offers intramural investigators three types of award – a program project award for a team of 3 to 5 independent investigators, a center/facility award, and an award for collaborations with extramural investigators or industry. The program made 25 awards to intramural investigators, ranging from \$48,000 to \$750,000 each, with a total of \$6.9 million dollars awarded. Read more at [2017-ddir innovation awards.pdf](#).

NIH Helpdesk Tickets for OTT Requests

Tim Leahy, NIH-OTT

In order to serve our customers more efficiently and to allow OTT to more closely manage and measure our interactions, we would like to remind folks to submit NIH IT Service Desk tickets rather than emailing OTT folks directly. Here is the link: <https://itservicedesk.nih.gov/support/>.

For all SharePoint inquiries, select: Office of Technology Transfer (OTT) SP

For NIH TechTracS and other inquiries (see examples listed below) select:

Office of Technology Transfer (OTT) NIH TechTracS

- NIH TechTracS Data Entry questions
- NIH TechTracS How-To questions
- NIH TechTracS Report Generation
- NIH TechTracS Data Integrity Issues
- CPI system questions
- Annuities/Maintenance questions
- EIR questions
- Records retention questions
- Patent/Patent family questions
- Status updates for EIRs, Patents, License Agreements, and Annuity payments

If you cannot access the NIH IT Service Desk system, please contact Tim Leahy.

Reminder about NIH TechTracS New End Users

Tim Leahy, NIH-OTT

For any new individual needing NIH TechTracS access, we will need their Supervisor to submit a Help Desk Ticket on their behalf, identifying the new End User's full name, Domain login id, and the role(s) they will need, e.g. Supervisor, Program Specialist, LPM, CRADA Admin, Federal Register Notices (FRN), License Number Creation, or Read Only. If we don't have this information in the initial help desk ticket, access to NIH TechTracS will be delayed.

Detecting Discrepancies between the Notices of Recordation and What Appears in NIH TechTracS

Jill Roering, NIH-OTT

To assist the Technology Licensing and Patent Manager (TLS, LPM, TTM, or TTPM) with identifying potential errors when generating future RDFs, the Docketing Group is providing alerts when encountering discrepancies between the inventors listed in NIH TechTracS and the inventors appearing on the Notices of Recordation.

When encountering these alerts it is an excellent time to verify the inventors and IC affiliations are correctly listed in NIH TechTracS and to verify the inventors at time of priority filing & PCT.

The Notices of Recordation discrepancy alerts will appear in the weekly docketing summaries reports. The following is an example;

“... Inventors Drs. Maddie Scientist and Sure Inventsalot are listed on the Notice of Recordation, however they are not listed in NIH TechTracS. Please ensure that this discrepancy is examined and, if applicable, update NIH TechTracS to ensure that all Inventors are correctly listed in each genus. Doing so will allow for future Royalty Distribution Forms (RDFs) to generate correctly and Royalty payments distributed correctly.”

FY-2016 Top 20 Commercially Successful Inventions

(based on royalties on product sales)

VACCINES & THERAPEUTICS

| Rank | | | |
|------|--|-----------------|-------|
| 1 | Novel Protease Inhibitor for Treatment of Drug-Resistant HIV-1 | Erickson et al. | NCI |
| 2 | HPV Vaccines Based Upon Recombinant Papillomavirus Capsid Proteins | Lowy et al. | NCI |
| 3 | Proteosome Inhibitor for Treatment of Multiple Myeloma | Gupta et al. | NCI |
| 4 | Nutritional Supplement to Treat Macular Degeneration | Ferris et al. | NEI |
| 9 | Palifermin for Treatment of Oral Mucositis | Rubin et al. | NCI |
| 11 | Vaccine for Dengue Virus | Lai et al. | NIAID |
| 18 | Development of Human Monoclonal Antibodies and Antibody Drug Conjugates Against CD276 as Cancer Diagnostics and Therapeutic Agents | Dimitrov et al. | NCI |
| 19 | Chimeric Antigen Receptors Targeting B-cell Maturation Antigen | Kochenderfer | NCI |

DIAGNOSTICS

| Rank | | | |
|------|--|-------------------|-------|
| 6 | DNA Probe for Breast Cancer Diagnosis (HER-2) | King et al. | NCI |
| 8 | Human Immunodeficiency Viruses Associated with AIDS, A Diagnostic Method for AIDS and Pre-AIDS, A Kit Therefor | Montagnier et al. | NCI |
| 14 | Process for Producing Monoclonal Antibodies Reactive with Human Breast Cancer | Schlom et al. | NCI |
| 16 | Parvovirus Capsids | Young et al. | NHLBI |

INSTRUMENTATION AND DEVICES

| Rank | | | |
|------|--|---------------|------|
| 10 | Transcranial Magnetic Stimulation System | Zangen et al. | NIDA |
| 12 | Laser Capture Microdissection | Liotta et al. | NCI |

RESEARCH MATERIALS

| Rank | | | |
|------|---|------------------|-------|
| 5 | Monoclonal Hybridoma Cell Lines | Murphy et al. | NIAID |
| 7 | Digital PCR | Silver et al. | NIAID |
| 13 | Monoclonal Antibody Reactive with Human Breast Cancer (TAG72) | Schlom et al. | NCI |
| 15 | Cloning, Expression and Diagnosis of Human Cytochrome P450 2C19 | Goldstein et al. | NIEHS |
| 17 | Mouse Expressing Enhanced Signaling for Bone Morphogenetic Protein (BMP): A Model For Human Disease | Mishina et al. | NIEHS |
| 20 | Synthetic Peptides for the Production of Specific Keratin Protein Antibodies | Yuspa et al. | NCI |

New TT Community Staff Members



William Dee, J.D.
NCI TTC - Shady Grove
Tech Transfer Manager



Abritee Dhal, Ph.D.
NCI TTC - Shady Grove
CRTA Fellow



Taryn Dick, Ph.D.
NCI TTC - Frederick
Fellow



Michelle Favila, Ph.D.
NCI TTC - Shady Grove
Fellow




Kimberly Griffin, Ph.D.
NCI TTC - Frederick
Tech Transfer Manager




Lynne Huang, Ph.D.
NCI TTC - Shady Grove
Tech Transfer Manager



Ricquita D. Pollard, Ph.D.
NCI TTC - Shady Grove
Tech Transfer Manager



Laura Prestia, Ph.D.
NCI TTC - Shady Grove
Tech Transfer Manager



Par Purnell
NCI TTC - Shady Grove
Program Specialist



James Simmons, Ph.D.
NCI TTC - Frederick
CRTA Fellow



Benfeard Williams, Ph.D.
NCI TTC - Shady Grove
Fellow

New TT Community Staff Members

William Dee, J.D., joined the NCI TTC CSC in January of 2017 as a Technology Transfer Manager. Prior to joining NIH, he was Sr. IP counsel at Covidien, a medical device company south of Boston. Bill received his J.D. and M.B.A. from Boston University and his B.S. in Chemical Engineering and M.S. in Biotechnology from Northeastern University.

Abritee Dhal, Ph.D., joined NCI TTC as CRTA fellow at the Shady Grove office in June 2017. Dhal joined the TTC after receiving her Ph.D. in Molecular Medicine and Translational Science from Wake Forest University in May 2017. She did her graduate research at Wake Forest Institute for Regenerative Medicine. Her dissertation project focused on the expansion and maintenance of human liver sinusoidal endothelial cells on various extracellular matrix (ECM) proteins, scaffolds, and coculture systems. While at Wake Forest, Dhal also gained technology transfer experience by working as a Technology Commercialization Intern for Wake Forest Innovations.

Taryn Dick, Ph.D., is a new fellow based in NCI TTC's Frederick office. Upon joining TTC in July 2017 she will split her time between TTC's IDMU and docket work for Frederick investigators in the Unit led by Jeff Thomas, Ph.D. Prior to joining TTC, she completed her post-doctoral training at the Penn State University College of Medicine. Dr. Dick has a Ph.D. in Molecular Toxicology and an MBA. She also gained technology transfer experience as a fellow in the Penn State Office of Technology Development.

Michelle Favila, Ph.D., joined NCI TTC in August as a fellow in the Unit of Lisa Finkelstein, Ph.D. Prior to joining TTC, Favila was a marketing trainee in the Office of Technology Transfer at the Washington University in St. Louis. Favila earned her doctorate at the University of Notre Dame, and then worked as a post-doc at IDRI, a Seattle not-for profit biotech, and at Washington University.

Kimberly Griffin, Ph.D., joined TTC's Frederick Unit as a technology transfer manager in January 2017 after initially joining TTC as a CRTA fellow in July 2015. Prior to joining TTC, Kim was an academic lecturer at California Polytechnic State University and Gonzaga University, where she taught undergraduate general and organic chemistry. She also interned in the Technology Transfer and Business Development office at Oregon Health Science University in Portland, OR. Kim holds a B.S. in chemistry from the University of California at Berkeley and a Ph.D. in organic chemistry from the University of Chicago.

Lynne Huang, Ph.D., initially joined TTC in February 2014 as a CRTA fellow. In December 2016, she accepted a technology transfer and patent specialist position in TTC's Competitive Service Center (CSC) unit to oversee the patent and licensing activities of the National Eye Institute (NEI), the National Institute on Child Health and Human Development (NICHD) and the National Institute of Complementary and Integrative Health (NCCIH). Huang received her Ph.D. in infectious diseases and pathology from the University of Florida, Gainesville, FL. Her graduate training focused on the molecular mechanism of host-parasite interactions. After graduation, she joined the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Clinical Infectious Diseases, where she did her two-year, post-doctoral research studying the mechanism of post-bacterial infection triglyceride accumulation. She became a USPTO-registered patent agent in 2012, and later interned with NIH OTT and the technology transfer office of National Human Genome Research Institute (NHGRI), where she gained valuable experience in patent evaluation, biotechnology marketing, and technology transfer agreements.

New TT Community Staff Members

Ricquita D. Pollard, Ph.D., started with NCI TTC in September 2015 as a CRTA fellow, and in January 2017 she accepted a technology transfer manager position. Prior to joining TTC, Ricquita pursued pre-doctoral studies at Wake Forest University with a focus on lipid sciences and cardiovascular diseases. Alongside her pre-doctoral studies, she interned in the Commercialization Services sector at the Wake Forest Innovations Office in Winston-Salem, NC. Ricquita holds a B.S. in Biology from Tuskegee University and a Ph.D. in Molecular Pathology from Wake Forest University.

Laura Prestia, Ph.D., joined TTC's Invention Development and Marketing Unit (IDMU) in December 2016. She previously joined TTC as a CRTA fellow in March 2016 where her training spanned technology transfer transactions, licensing and patenting. She is also a co-founder of the NCI Technology Transfer Ambassadors Program to empower post-doctoral innovation and an entrepreneurial lab-to-market mindset. Prior to joining NCI, Laura was an IRTA fellow within the CDC Unit at the NIH OTT (which moved to NIAID). Prior to joining the NIH, Laura received her Ph.D. in Neuroscience from the State University of New York (SUNY) Upstate Medical University. During this time, Laura also worked with two Syracuse-based incubators, SUNY Upstate's technology transfer office, completed Technology Transactions coursework at Syracuse University College of Law, and interned with the New York State Science and Technology Law Center.

Par Purnell joined TTC as a program specialist for license administration in March 2017. Par comes to TTC with extensive administrative experience working for membership associations. She has a B.A. in Business Administration from Southern Illinois University and she recently received an Associate's degree in Applied Sciences in Health Information Technology from Kaplan University.

James Simmons, Ph.D., joined TTC as a CRTA fellow at the Frederick office in March 2017. He will focus on technology transfer transactions, patenting, and licensing during his fellowship. Prior to joining NCI, he worked at Leidos Biomedical developing vaccines for cancer prevention. Before that, James completed his post-doctoral research at the University of Virginia investigating the mechanism of Ebolavirus entry into host cells. He received his Ph.D. in Chemistry from Emory University. His graduate research focused on amyloid peptide self-assembly and the interaction between these peptides and phospholipid membranes for understanding Alzheimer's disease.

Benfeard Williams, Ph.D., is a new fellow in the Unit led by Michael Pollack, Ph.D. He received his doctorate in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill (UNC). The focus of his graduate training was protein misfolding in neurodegenerative diseases and RNA tertiary structure modeling. Dr. Williams also completed an internship with the Office of Commercialization and Economic Development at UNC, where he worked on chemistry and applied physics-related technologies.

Please forward articles and newsletter suggestions to Jill Roering at roeringj@mail.nih.gov.

